Comparison of <scp>MiniMed 780G</scp> system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users

Abstract

This real-world analysis shows that more than 75% of users with T1D aged 15 years or younger using the MiniMed 780G system achieved international consensus-recommended glycaemic control, mirroring the achievements of the population aged older than 15 years.